The life sciences industry is dealing with a series of global challenges relating to increasing competition, escalating costs and expanding regulatory requirements. New regulations and requirements related to transparent interactions between life sciences companies and physicians, allied health providers and others (collectively, “Healthcare Professionals” or “HCPs”), are being implemented by governments and industry associations throughout the world. Anti-corruption laws (e.g., The Foreign Corrupt Practices Act in the U.S. and the U.K. Bribery Act) are now more easily enforced with the implementation of the new transparency requirements.
The presenters bring in-depth experience and different points of view from the standpoint of the life sciences, legal and regulatory and valuation communities:
- Jan E. Murray, Esq., Of Counsel, Foley & Lardner, LLP
- Ann S. Brandt, PhD, Partner, HealthCare Appraisers, Inc.
- Colleen Evans, Global Commercial Compliance Manager, GE Healthcare